Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Stock Soars 15 Percent on Positive Biomarker Study Data

NEW YORK, June 6 (GenomeWeb News) - Shares in Ciphergen Biosystems were up 15 percent, or $.17, at $1.29 in mid-day trading today after the company yesterday presented favorable results from a study evaluating the use of its biomarkers to detect ovarian cancer.


Under the study, 607 patient samples provided by five international medical centers were evaluated for seven biomarkers. Approximately 61 percent, or 373 women, were found to have invasive epithelial ovarian cancer. Of those with cancer, 27 percent were in the early stages. The remaining women had benign gynecologic disease.


All seven biomarkers individually demonstrated statistically significant power to differentiate ovarian cancer patients from women with benign disease, Ciphergen said.


Ciphergen conducted the study as part of a comprehensive ovarian cancer program in conjunction with The Johns Hopkins School of Medicine, the University of Texas M.D. Anderson Cancer Center, University College London, and the University of Kentucky.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.